Advanced search
Publication Cover
Pharmaceutical Development and Technology Volume 23, 2018 - Issue 3: Issue Theme: Ocular, otic, nasal, rectal and vaginal formulation innovations and regulatory considerations
Submit an article Journal homepage
243
Views
10
CrossRef citations to date
0
Altmetric
Ocular

Preparation of dexamethasone ophthalmic implants: a comparative study of in vitro release profiles

Ana I. PrataFaculty of Pharmacy, University of Coimbra, Coimbra, Portugal;
,
Patrícia CoimbraCIEPQPF, Department of Chemical Engineering, University of Coimbra, Coimbra, Portugal
&
M. Eugénia PinaFaculty of Pharmacy, University of Coimbra, Coimbra, Portugal; ;CIEPQPF, Department of Chemical Engineering, University of Coimbra, Coimbra, PortugalCorrespondence[email protected]
Pages 218-224 | Received 18 Jul 2016, Accepted 06 Feb 2017, Published online: 30 Mar 2017

References

  • Arevalo JF. 2014. Diabetic macular edema: changing treatment paradigms. Curr Opin Ophthalmol. 25:502–507.
  • Barcia E, Herradon C, Herrero-Vanrell R. 2005. Biodegradable additives modulate ganciclovir release rate from PLGA microspheres destined to intraocular administration. LDDD. 2:184–193.
  • Bibliowicz J, Tittle RK, Gross JM. 2011. Toward a better understanding of human eye disease: insights from the Zebrafish, Danio rerio. In: Chang KT, Min KT, editors. Animal models of human disease. San Diego: Elsevier Academic Press Inc.; p. 287–330.
  • Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex CHAMPLAIN Study Group. 2011. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 31:915–923.
  • Cabrera M, Yeh S, Albini TA. 2014. Sustained-release corticosteroid options. J Ophthalmol. 2014:164692.
  • Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. 2011a. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 52:80–86.
  • Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF. 2011b. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 52:4605–4609.
  • Chen H. 2015. Recent developments in ocular drug delivery. J Drug Target. 23:597–604.
  • Dash AK, Cudworth GC. 1998. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 40:1–12.
  • de Smet MD. 2012. Corticosteroid intravitreal implants. In: Miserocchi E, Modorati G, Foster CS, editors. New treatments in noninfectious uveitis. Basel: Karger; p. 122–133.
  • Fialho SL, Behar-Cohen F, Cunha AS. 2008. Dexamethasone-loaded poly (ɛ-caprolactone) intravitreal implants: a pilot study. Eur J Pharm Biopharm. 68:637–646.
  • Fialho SL, Júnior ASC. 2007. Drug delivery systems for the posterior segment of the eye: fundamental basis and applications. Arq Bras Oftalmol. 70:173–179.
  • Gaudana R, Ananthula HK, Parenky A, Mitra AK. 2010. Ocular drug delivery. AAPS J. 12:348–360.
  • Hunter RS, Lobo AM. 2011. Dexamethasone intravitreal implant for the treatment of non-infections uveitis. Clin Ophthalmol. 5:1613–1621.
  • Maia J, Ribeiro MP, Ventura C, Carvalho RA, Correia IJ, Gil MH. 2009. Ocular injectable formulation assessment for oxidized dextran-based hydrogels. Acta Biomater. 5:1948–1955.
  • Miserocchi E, Fogliato G. 2013. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 23:705–717.
  • Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. 2004. Global data on visual impairment in the year 2002. Bull World Health Organ. 82:844–851.
  • Sapieha P, Hamel D. 2010. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol. 42:5–12.
  • Short BG. 2008. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 36:49–62.
  • Taylor SR, Isa H, Joshi L, Lightman S. 2010. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 224:46–53.
  • van Wijngaarden P, Qureshi SH. 2008. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom. 91:427–437.
  • Zhang X, Zeng H. 2014. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 4:27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.